[Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?]

Nefrologia. 2008;28(2):129-34.
[Article in Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Chelating Agents / economics*
  • Chelating Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Humans
  • Hyperphosphatemia / drug therapy*
  • Hyperphosphatemia / economics*
  • Hyperphosphatemia / etiology
  • Kidney Failure, Chronic / complications
  • Phosphates* / metabolism
  • Practice Guidelines as Topic

Substances

  • Chelating Agents
  • Phosphates